Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMS 2022 | The potential of inhibiting SUMOylation as a therapeutic strategy in multiple myeloma

Li Du • 27 Aug 2022
IMS 2022
Multiple Myeloma Dexamethasone Lenalidomide

Li Du, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, highlights the potential of inhibition sumoylation to increase the cytotoxicity of existing anti-myeloma therapies. Dr Du explains that previous experiments have shown that inhibiting SUMO E1 potentiates the effect of lenalidomide and dexamethasone and immunotherapies. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Li Du

0:56
Improving the efficacy of CAR-T therapy in multiple myeloma through SUMOylation inhibition
Li Du • 27 Aug 2022

Related Videos

1:47
Looking forward to the Miami Myeloma MRD Virtual Meeting 2024
Ola Landgren • 13 Apr 2024
2:27
The encouraging results of the LINKER-MM1 trial: safety and efficacy of linvoseltamab in R/R myeloma
Faith Davies • 9 Apr 2024
0:37
Upcoming studies investigating linvoseltamab in myeloma
Faith Davies • 9 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals